Clearside reports Q2 2021 net loss $6.1M; OASIS Cohort 2 underway; XIPERE PDUFA Oct 30

Clearside Biomedical, Inc.

Net loss of $6.1M ($0.11/share) vs $5.8M ($0.13/share) in Q2 2020.
Revenue of $0.8M from partner licensing; cash $26.4M to fund ops into Q2 2022.
OASIS Phase 1/2a wet AMD: Cohort 1 met safety endpoints; Cohort 2 enrollment (0.1 mg dose) underway.
XIPERE NDA resubmission accepted; FDA PDUFA action date of October 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.